FDA whistle-blower David Graham says European health authorities should reconsider their approval of Merck's arthritis painkiller Arcoxia, which he says is "clearly killing people." An FDA advisory panel last week recommended the agency not approve the drug for the U.S. market, but Merck said the "overall benefit-to-risk profile" favors Arcoxia.

Full Story:
USA Today

Related Summaries